Genzyme Puts Up $22M To Settle FCA Claims

Law360, Los Angeles (December 20, 2013, 8:43 PM ET) -- Genzyme Corp. has agreed to pay more than $22 million to resolve former employees' False Claims Act allegations that it marketed its Seprafilm adhesion barrier for unapproved uses, according to court documents filed Friday. 

The settlement will resolve claims in a pair of whistleblower lawsuits brought by former Genzyme employees and a doctor. According to the U.S. Department of Justice, Genzyme sales representatives marketed Seprafilm for unapproved surgical uses that were not reimbursable under federal health care programs. 

“There will be consequences when medical device companies...
To view the full article, take a free trial now.
Try Law360 for free for seven days
Already a subscriber? Click here to login

Already have access?

  1. Forgot your password?
  2. Sign In

Get instant access to the one-stop news source for business lawyers

Required